JP2022515330A5 - - Google Patents
Info
- Publication number
- JP2022515330A5 JP2022515330A5 JP2021531831A JP2021531831A JP2022515330A5 JP 2022515330 A5 JP2022515330 A5 JP 2022515330A5 JP 2021531831 A JP2021531831 A JP 2021531831A JP 2021531831 A JP2021531831 A JP 2021531831A JP 2022515330 A5 JP2022515330 A5 JP 2022515330A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- acid sequence
- tmmp
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782167P | 2018-12-19 | 2018-12-19 | |
| US62/782,167 | 2018-12-19 | ||
| US201962814684P | 2019-03-06 | 2019-03-06 | |
| US62/814,684 | 2019-03-06 | ||
| PCT/US2019/067575 WO2020132297A1 (en) | 2018-12-19 | 2019-12-19 | Multimeric t-cell modulatory polypeptides and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022515330A JP2022515330A (ja) | 2022-02-18 |
| JP2022515330A5 true JP2022515330A5 (enExample) | 2022-12-26 |
| JP7549579B2 JP7549579B2 (ja) | 2024-09-11 |
Family
ID=71100921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531831A Active JP7549579B2 (ja) | 2018-12-19 | 2019-12-19 | 多量体ｔ細胞調節ポリペプチド及びその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20220112252A1 (enExample) |
| EP (2) | EP4650365A3 (enExample) |
| JP (1) | JP7549579B2 (enExample) |
| KR (1) | KR20210104673A (enExample) |
| CN (1) | CN113286609B (enExample) |
| AU (1) | AU2019404285B2 (enExample) |
| BR (1) | BR112021011814A2 (enExample) |
| CA (1) | CA3113100A1 (enExample) |
| DK (1) | DK3897701T3 (enExample) |
| ES (1) | ES3052836T3 (enExample) |
| IL (1) | IL281505B1 (enExample) |
| MX (1) | MX2021007287A (enExample) |
| MY (1) | MY206813A (enExample) |
| PH (1) | PH12021500027A1 (enExample) |
| SG (1) | SG11202103863UA (enExample) |
| SI (1) | SI3897701T1 (enExample) |
| TW (1) | TWI856047B (enExample) |
| WO (1) | WO2020132297A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017201210A1 (en) * | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| ES2973548T3 (es) | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| US20200010528A1 (en) | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| JP2020534352A (ja) | 2017-09-07 | 2020-11-26 | キュー バイオファーマ，インコーポレーテッド | コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法 |
| WO2021230638A1 (en) * | 2020-05-12 | 2021-11-18 | Lg Chem, Ltd. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| IL299834A (en) * | 2020-07-14 | 2023-03-01 | Cue Biopharma Inc | with binding sites and methods for using them T - cellular modulatory polypeptides |
| WO2022099157A1 (en) * | 2020-11-06 | 2022-05-12 | Cue Biopharma, Inc. | Antigen presenting polypeptide complexes and methods of use thereof |
| WO2022197970A2 (en) * | 2021-03-19 | 2022-09-22 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| AU2022238389A1 (en) * | 2021-03-19 | 2023-10-05 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| WO2023081718A1 (en) * | 2021-11-04 | 2023-05-11 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| CN114805538B (zh) * | 2022-05-20 | 2023-06-09 | 广州智瓴生物医药有限公司 | 一种增强til功效的培养方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| AU687117B2 (en) | 1993-10-25 | 1998-02-19 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
| US7078387B1 (en) | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| AU2007223855B2 (en) | 2006-03-06 | 2013-05-16 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
| JP2010536341A (ja) | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| ES2610356T3 (es) | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| US9205144B2 (en) | 2011-06-03 | 2015-12-08 | Dana-Farber Cancer Institute, Inc. | Identification of conserved peptide blocks in homologous polypeptides |
| RS61173B1 (sr) * | 2013-01-15 | 2021-01-29 | Memorial Sloan Kettering Cancer Center | Imunogeni wt-1 peptidi i postupci za njihovu upotrebu |
| WO2015195531A2 (en) | 2014-06-18 | 2015-12-23 | Albert Einstein College Of Medicine, Inc. | Syntac polypeptides and uses thereof |
| DK3186283T3 (da) | 2014-08-29 | 2020-03-02 | Hoffmann La Roche | Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1 |
| EP4406604A3 (en) | 2015-03-05 | 2024-10-23 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| SMT202200370T1 (it) * | 2015-11-20 | 2022-11-18 | Memorial Sloan Kettering Cancer Center | Composizione per il trattamento del cancro |
| WO2017201210A1 (en) * | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| ES2973548T3 (es) * | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| US20200010528A1 (en) * | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| CN119409836A (zh) * | 2017-03-17 | 2025-02-11 | 弗雷德哈钦森癌症中心 | 免疫调节融合蛋白及其用途 |
| EP3678691A4 (en) * | 2017-09-07 | 2021-06-09 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| JP2020534352A (ja) * | 2017-09-07 | 2020-11-26 | キュー バイオファーマ，インコーポレーテッド | コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法 |
| WO2020132366A2 (en) * | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| WO2020132365A2 (en) * | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| EP3897690A4 (en) * | 2018-12-19 | 2022-09-28 | Cue Biopharma, Inc. | T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| CA3146591A1 (en) * | 2019-09-20 | 2021-03-25 | Ronald D. Seidel Iii | T-cell modulatory polypeptides and methods of use thereof |
| US20230117521A1 (en) * | 2020-03-25 | 2023-04-20 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| WO2021231376A2 (en) * | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| AU2022238389A1 (en) * | 2021-03-19 | 2023-10-05 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
-
2019
- 2019-12-18 TW TW108146526A patent/TWI856047B/zh active
- 2019-12-19 WO PCT/US2019/067575 patent/WO2020132297A1/en not_active Ceased
- 2019-12-19 EP EP25193554.0A patent/EP4650365A3/en active Pending
- 2019-12-19 CN CN201980080657.4A patent/CN113286609B/zh active Active
- 2019-12-19 SG SG11202103863UA patent/SG11202103863UA/en unknown
- 2019-12-19 PH PH1/2021/500027A patent/PH12021500027A1/en unknown
- 2019-12-19 IL IL281505A patent/IL281505B1/en unknown
- 2019-12-19 AU AU2019404285A patent/AU2019404285B2/en active Active
- 2019-12-19 MY MYPI2021001671A patent/MY206813A/en unknown
- 2019-12-19 JP JP2021531831A patent/JP7549579B2/ja active Active
- 2019-12-19 SI SI201930988T patent/SI3897701T1/sl unknown
- 2019-12-19 ES ES19900784T patent/ES3052836T3/es active Active
- 2019-12-19 EP EP19900784.0A patent/EP3897701B1/en active Active
- 2019-12-19 DK DK19900784.0T patent/DK3897701T3/da active
- 2019-12-19 KR KR1020217015556A patent/KR20210104673A/ko not_active Ceased
- 2019-12-19 BR BR112021011814A patent/BR112021011814A2/pt unknown
- 2019-12-19 MX MX2021007287A patent/MX2021007287A/es unknown
- 2019-12-19 CA CA3113100A patent/CA3113100A1/en active Pending
-
2021
- 2021-05-21 US US17/326,837 patent/US20220112252A1/en not_active Abandoned
-
2024
- 2024-07-10 US US18/768,830 patent/US20250074960A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022515330A5 (enExample) | ||
| JP2022536581A5 (enExample) | ||
| JP7270001B2 (ja) | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ－ａ３を認識するｔ細胞受容体 | |
| JP2019512222A5 (enExample) | ||
| JP2021500855A5 (enExample) | ||
| JP7573075B2 (ja) | 変異型ｐ５３を認識するｔ細胞受容体 | |
| JP7385566B2 (ja) | 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体 | |
| Kelly et al. | A new human HLA class II-related locus, DM | |
| IL272085B2 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| JP2020511949A5 (enExample) | ||
| IL308851B2 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| JP2021191265A5 (enExample) | ||
| JP7635165B2 (ja) | ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体 | |
| JP2019522466A5 (enExample) | ||
| JP2022515331A5 (enExample) | ||
| JP2020533273A5 (enExample) | ||
| JP2023526723A5 (enExample) | ||
| JP2017519491A5 (enExample) | ||
| JP2015535816A5 (enExample) | ||
| WO2020082130A1 (en) | T-cell receptors and uses thereof | |
| JP2010527919A5 (enExample) | ||
| RS55609B1 (sr) | Fc fuzioni proteini koji sadrže nove linkere ili aranžmane | |
| JP7735285B2 (ja) | Ｇ１２ｖ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体 | |
| JP7742354B2 (ja) | Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体 | |
| JP2024517884A (ja) | ｐ５３におけるＣ１３５Ｙ、Ｒ１７５Ｈ又はＭ２３７Ｉ変異を認識するＴ細胞受容体 |